Latest Boehringer Ingelheim Stories
Sales of the LABA/LAMA Combination Drug Class are Expected to Grow Significantly Over the Next Six Months, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug.
Hot Line session presentations to feature renal function data from pivotal RE-LY® trial and global GLORIA(TM)-AF registry updates RIDGEFIELD, Conn., Aug.
Top Healthcare Talent, Companies and Brand Champions to be Honored September 18th New York, NY (PRWEB) August 20, 2014 The finalists are in for the sixth-annual
INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire/ -- The U.S.
All Aspects Of Litigation Surrounding The Federal Pradaxa Lawsuits Alleging Boehringer Ingelheim's Blood Thinner Caused Serious Internal Bleeding Have Been Suspended Until Completion Of A
Committee Voted Based on Clinical Data from Eight Efficacy Trials RIDGEFIELD, Conn., Aug. 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
Thousands of Pradaxa Lawsuits Currently Pending in U.S.
Donna Ames is recognized as an NAPW VIP Woman of the Year for her
AstraZeneca, Boehringer Ingelheim, Eli Lilly & Company, Ferring Pharmaceuticals, Inc., Forest Laboratories, Inc., GlaxoSmithKline, Novartis, Novo Nordisk, Pearl Therapeutics, Pfizer, Sanofi, Chiltern
Third product from the BI-Lilly Diabetes alliance to be approved by FDA RIDGEFIELD, Conn., and INDIANAPOLIS, Aug. 1, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc.
- In the month which preceded the present; in the last month, as distinguished from the current or present month and all others.